Publications by authors named "Amy G Cutrell"
Article Synopsis
- Expanded analysis of predictors of confirmed virologic failure (CVF) in 1651 participants taking cabotegravir + rilpivirine long-acting (CAB + RPV LA) included data beyond 48 weeks and considered various demographic and viral factors.
- Results showed that 1.4% of participants experienced CVF, with risks increasing for those with mutations associated with rilpivirine resistance, specific HIV subtypes, and higher body mass index.
- The study concluded that having two or more of these baseline factors has a significant impact on the risk of CVF, indicating the importance of these factors in effectively managing treatment with CAB + RPV LA.
Article Synopsis
- The study aimed to analyze the pharmacokinetics of cabotegravir, focusing on how different factors (both intrinsic and extrinsic) affect the drug's variability in the body using data from various clinical trials.
- Researchers utilized advanced statistical tools like NONMEM and R to evaluate a large dataset of plasma concentrations from HIV-1-infected and uninfected subjects, testing different dosing methods and identifying trends related to demographics and health metrics.
- The findings suggest a population pharmacokinetic model that can guide dosing strategies without necessitating adjustments based on individual factors like race or age, highlighting certain influences from smoking and body metrics on drug absorption and clearance.
Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with virologic failure at Week 48 were evaluated post hoc.
Design And Methods: Data from 1039 adults naive to long-acting CAB+RPV were pooled in a multivariable analysis to examine the influence of baseline viral and participant factors, dosing regimen and drug concentrations on confirmed virologic failure (CVF) occurrence using a logistic regression model.
Background: Recently, the Data collection of Adverse events of Anti-HIV Drugs Group (D:A:D) described results from their international observational cohort of 33,347 HIV-1-infected individuals, suggesting unexpected increased risk of myocardial infarction (MI) associated with abacavir (ABC) therapy [relative rate 1.9, 95% confidence interval (CI): 1.47 to 2.
View Article and Find Full Text PDF